• In July 2026, Merck announced an early, multi-pronged access plan for its investigational once-monthly HIV PrEP pill alimatravir (MK-8527), including royalty-free voluntary licensing with seven generic manufacturers to supply 129 low- and middle-income countries following potential regulatory approvals.
• This move, which includes regional manufacturing in Africa and Latin America and licensing deals signed even before Phase 3 enrollment completion, marks a first-of-its-kind early access approach in HIV prevention that could reshape how global health considerations are integrated into drug commercialization plans.
• We’ll now examine how Merck’s early, royalty-free licensing of alimatravir to 129 countries may influence its broader investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 17 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Merck Investment Narrative Recap

To own Merck, you need to believe its broad pipeline and new launches can offset eventual KEYTRUDA patent risks while supporting earnings growth. The alimatravir HIV PrEP access plan is directionally important for Merck’s infectious disease ambitions, but it does not change the near term focus on oncology and cardiometabolic launches as key catalysts, or the concentration risk from KEYTRUDA as the central overhang.

Among Merck’s recent news, the FDA approval of LIPFENDRA, the first oral PCSK9 inhibitor, stands out next to the alimatravir update. Both highlight how Merck is pushing into large chronic disease and prevention markets, broadening its portfolio beyond oncology. For investors watching near term catalysts, LIPFENDRA’s commercial rollout and further KEYTRUDA label expansions remain far more central to the story than early royalty free licensing for an investigational HIV PrEP.

Yet beneath this progress, investors should also be aware that Merck’s heavy reliance on KEYTRUDA leaves future revenues exposed if late stage assets like alimatravir or LIPFENDRA do not...

Merck's narrative projects $74.6 billion revenue and $22.3 billion earnings by 2029. This requires 4.3% yearly revenue growth and an earnings increase of about $13.4 billion from $8.9 billion today.

Uncover how Merck's forecasts yield a $132.78 fair value, in line with its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming Merck could lift annual revenue to about US$79.6 billion and earnings to roughly US$26.2 billion by 2029, and this new alimatravir access plan could either support that view or prompt a rethink, depending on how you see the trade off between global access and future margins.

Explore 8 other fair value estimates on Merck - why the stock might be worth as much as 65% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Merck research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Merck research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Merck's overall financial health at a glance.

Contemplating Other Strategies?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Find 49 companies with promising cash flow potential yet trading below their fair value.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.
• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.